Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Raises Price Target to $40
Crescent Biopharma: Q3 Earnings Snapshot
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma Q3 EPS $(0.90) Misses $(0.72) Estimate, Sales $3.117M Beat $312.500K Estimate
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma to Present at November Investor Conferences
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady
Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Crescent Biopharma to Present at September Investor Conferences
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.